Therefore, these results could corroborate previously published information showing a relationship between disease-free survival or overall survival in patients with ER−and triple-negative BRCA (Liu et al., 2012) or HER2+ (Hou et al., 2018) and the presence of CD8+ T lymphocytes infiltrated in the tumor, which could indicate that changes in the expression of P2X7 in these BRCA subtypes could be used as a marker of worse prognosis and the survival of these patients. Here, P2RX7 is linked to neoplasm.